葡萄膜黑色素瘤的免疫基础：免疫治疗是否有理论依据？
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
作者信息
Rossi Ernesto, Schinzari Giovanni, Zizzari Ilaria Grazia, Maiorano Brigida Anna, Pagliara Monica Maria, Sammarco Maria Grazia, Fiorentino Vincenzo, Petrone Gianluigi, Cassano Alessandra, Rindi Guido, Bria Emilio, Blasi Maria Antonietta, Nuti Marianna, Tortora Giampaolo
机构信息
Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, 00168 Rome, Italy.
Medical Oncology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
出版信息
Cancers (Basel). 2019 Jul 26;11(8):1055. doi: 10.3390/cancers11081055.
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
目前尚未确立转移性葡萄膜黑色素瘤（mUM）的标准治疗方法。尽管葡萄膜黑色素瘤尚未纳入使用检查点抑制剂的III期临床试验，但免疫疗法仍是该疾病的常用治疗方法。不幸的是，只有少数患者通过免疫疗法获得临床益处。为了解免疫疗法是否仍能在该疾病中发挥作用，对mUM的免疫特征进行了综述。
Zotero 插件